What is Acrivon Therapeutics, Inc. Common Stock's Shariah compliance score?

Acrivon Therapeutics, Inc. Common Stock's (ACRV) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Acrivon Therapeutics, Inc. Common Stock pass AAOIFI screening?

Acrivon Therapeutics, Inc. Common Stock (ACRV) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (ACRV: 2.9%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for Acrivon Therapeutics, Inc. Common Stock stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Acrivon Therapeutics, Inc. Common Stock (ACRV) using the latest financial data.

Where can I screen Acrivon Therapeutics, Inc. Common Stock for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Acrivon Therapeutics, Inc. Common Stock (ACRV) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about ACRV's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

ACRV: Is Acrivon Therapeutics, Inc. Common Stock Halal?

Acrivon Therapeutics, Inc. Common Stock

NASDAQHealthcareUS

$2.18

-0.91%

Market Cap: 93.3M

Compliance Status

Not Halal

Screened on Aug 26, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Acrivon Therapeutics, Inc. Common Stock (ACRV) halal? Not Halal. Based on AAOIFI screening, Acrivon Therapeutics, Inc. Common Stock passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

2.9% of 30.0% limit

What this means for you

Most scholars advise not holding ACRV

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 26, 2026

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

RGCA+

Regencell Bioscience Holdings Limited

$5.02

-4.92%

0001.KLA+

Supercomnet Technologies Bhd

$0.52

-0.02%

0002.KLA+

Kotra Industries Bhd

$3.72

-0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.38

-0.01%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track ACRV and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Acrivon Therapeutics, Inc. Common Stock (ACRV) halal to invest in?

Acrivon Therapeutics, Inc. Common Stock (ACRV) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Acrivon Therapeutics, Inc. Common Stock get a F compliance rating?

Acrivon Therapeutics, Inc. Common Stock (ACRV) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.9% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Acrivon Therapeutics, Inc. Common Stock's Shariah verdict?

Acrivon Therapeutics, Inc. Common Stock's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Acrivon Therapeutics, Inc. Common Stock re-screened for Shariah compliance?

Acrivon Therapeutics, Inc. Common Stock (ACRV) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 26, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.